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INTRODUCTION 
Since the outbreak of the COVID-19 pandemic towards the 
end of 2019, it has spread rapidly throughout the world and 
healthcare has had to adapt to the problem in ways that were 
previously thought unimaginable and certainly not anticipated. 
In a short space of time, a huge body of evidence has been 
gathered and disseminated, but it remains difficult to distinguish 
between hype, panic and fact. Specifically, it has been difficult 
to find facts that help interventional cardiologists adapt their 
clinical practice and patient care algorithms in a safe manner 
that benefits short- and long-term outcomes. However, the 
one truth that has emerged is that systems that are better 
prepared tend to do better than those that are not. To this 
end, we aim to provide some direction on how interventional 
cardiology may be affected and should be managed during the 
pandemic. 
The unique and specific challenge that COVID-19 brings to the 
interventional cardiologist is that we are no longer considering 
only what is best for the patient, but also the risk to healthcare 
practitioners, other patients, and the healthcare system. 
Although this review will be applicable at the time of writing, it 
is important to adjust the management of cases to the changes 
in the epidemic and healthcare capacity. 
RISK TO HEALTHCARE PROVIDERS
The risk of healthcare providers (HCP) contracting COVID-19 
in a specific setting is difficult to judge, because of different 
levels of protection and exposure in different environments. 
In a large cohort studied by the US Centres for Disease 
Control and Prevention, occupational status was known for 
49 370 out of 315 531 COVID-19 cases and 9 282 (19%) of 
these were HCPs. They reported contact with confirmed 
COVID-19 cases in a healthcare facility in only 55% of cases. 






The impact of the COVID-19 pandemic on our lives is 
unprecedented and major adjustments to our practices 
as physicians are required. Although our comments are 
applicable at the time of writing, the situation changes 
daily and the content of this article should be adjusted 
accordingly.
Cath lab: An unambiguous cath lab protocol should be 
drawn up for each facility, appropriate to local circum-
stances. This should include standard procedures in 
preparation for arrival at the lab, in the performance 
of procedures, and, importantly, in maintaining due 
diligence when removing protective gear. All team 
members should be well trained in these procedures.
Acute coronary syndromes: Standard timing for the 
invasive management of patients should not change 
during the pandemic. Due to delays often unavoidable 
during the pandemic, alternative strategies such as 
thrombolysis may be more readily available and there-
fore more appropriate.
Drugs: The sick COVID-19 patient often represents a 
pro-thrombotic state and operators should ensure 
adequate anti-thrombotic therapy. Knowledge of inter-
actions between cardiac drugs and investigational anti-
viral treatments is important.
Elective procedures: Patients with chronic cardiac 
conditions are at high risk and may require non-urgent 
procedures to avert major complications. Selecting 
these cases requires consideration of multiple risks and 
benefi ts.  SAHeart 2020;17:296-304
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Only 10% were hospitalised, 5% were admitted to ICU, and 
mortality was 0.6%.(1)
A recent systematic review of 64 publications on the epi-
demiology and risk to HCPs concluded that HCPs were at high 
risk for infection by virtue of significant exposure in the work-
place, but that the use of appropriate protective measures and 
equipment reduced this risk considerably.(2) When managing 
individual patients, the risk to healthcare providers depends on 
the risk of the patient having COVID-19 and the risk of the 
specific procedure. 
Patient risk categories
The WHO have provided definitions to classify patients based 
on the access to test results and patient symptoms, which give 
guidance to HCP of their risk exposure (see Table I).(3)
Procedure risk categories
The ESC have provided some guidance in classifying procedure 
risk and therefore recommendations for the level of personal 
protective equipment (PPE) required. Local availability of level 
III protection (the highest, requiring full-face respiratory 
protective devices or powered air-purifying respirators) is 
extremely limited and probably not applicable. For the inter-
ventional cardiologist, this implies that the highest level of 
protection is level II, which includes:
 ■ Disposable surgical cap
 ■ Medical protection mask (N95/ FFP2)
 ■ Work uniform
 ■ Lead apron
 ■ Gown
 ■ Goggles/visor
 ■ Disposable surgical gloves (ideally 2 pairs to enable safe 
removal)(4)
The above is considered appropriate for the following pro-
cedures on patients classified as suspected/probable or con-
firmed:
 ■ Trans-oesophageal echocardiogram (TOE)
 ■ Coronary angiography and PCI
 ■ EP studies
 ■ Cleaning of instruments used (e.g. TOE probes, 
stethoscope)(5)
Patient COVID-19 status
If a widely available, cheap test with immediate results were 
available, it would make sense to test all patients prior to 
admission. This would make decision-making in the hospital 
vastly simpler, despite the fact that a negative test does not 
exclude the disease. Availability of tests is however variable 
and results may take between 4 hours and 7 days. An indivi-
dualised approach is therefore required depending on local 
circumstances, although the ideal should be to test all patients 
on or prior to admission.(6) Where such testing is not available, 
all patients coming to the lab should wear surgical face masks. 
Patients who are intubated or presenting with STEMI or very 
high risk NSTEMI requiring urgent angiography, should be 
assumed to be COVID-19 positive.(6) We, however, have to 
concede that this has different implications for different environ-
ments. Options range from standard PPE for most cases, 
with an upgrade to full level II PPE in the case of a resuscitation 
in some hospitals, to full donning and doffing of level II PPE 
for all cath lab staff for all procedures, and cleaning of the lab 
after each such case in others.
TABLE I: Patient risk status as defined by the WHO(3)
Confi rmed A person with laboratory confi rmation of COVID-19 infection, irrespective of clinical signs and symptoms.
Probable
A. A suspect case for whom testing for the COVID-19 virus is inconclusive.
    OR
B. A suspect case for whom testing could not be performed for any reason.
Suspect case
A.  A patient with acute respiratory illness (fever and at least one sign/symptom of respiratory disease, e.g. cough, shortness of breath), 
AND a history of travel to or residence in a location reporting community transmission of COVID-19 disease during the 14 days 
prior to symptom onset;
    OR
B.   A patient with any acute respiratory illness AND having been in contact with a confi rmed or probable COVID-19 case (see 
defi nition of contact) in the last 14 days prior to symptom onset;
    OR
C.   A patient with severe acute respiratory illness (fever and at least one sign/symptom of respiratory disease, e.g. cough, shortness of 
breath; AND requiring hospitalisation) AND in the absence of an alternative diagnosis that fully explains the clinical presentation.
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CATH LAB PREPARATION
It is recommended that hospitals have standard operating pro-
cedures in place for COVID-19 positive/suspected patients 
and that these are well communicated to all personnel. If a 
hospital has more than one cath lab, then a single lab should be 
allocated to performing all procedures on COVID-19 positive 
patients. When choosing a lab dedicated to COVID-19 patients, 
one should bear in mind that the ESC recommends that the 
air-conditioning in the cath lab should do a minimum of 15 air 
replacements/hour, but ideally 30.(5) The dedicated lab should 
have all the equipment required outside the lab (with a desig-
nated runner to bring items to the door) or stored in cupboards 
with closed doors. Most cases performed will remain on 
COVID-19 negative patients, but having the lab set up in this 
manner will greatly reduce the time required to clean up after 
cases involving COVID-19 positive patients.
Donning and doffi ng
All HCPs involved should be trained in the correct use of 
PPE. These procedures should be done under supervision and 
especially doffing should always be supervised by a trained 
person – the so called “Dofficer”.(4)
Prior to patient’s arrival
 ■ Coordinate transport to ensure the patient does not have 
to wait outside the lab
 ■ For unstable patients: consider elective intubation under 
controlled circumstances prior to the procedure
 ■ Ensure the minimum number of people are in the lab
The procedure
 ■ Only people involved in the procedure should be in the 
room and nobody should leave the room until completion
 ■ Resuscitation is extremely high risk for aerosolisation of the 
virus and each lab should have a clear standard operating 
procedure for this
After the procedure
This part is probably the most important safety aspect of 
dealing with COVID patients. The EAPCI position statement 
recommends the following:
 ■ Keep the door closed
 ■ Supervised doffing. This should be done inside the lab. The 
facial respirator should be removed outside the cath lab at 
the end
 ■ Do not squeeze contaminated materials into the waste 
container in order to avoid aerosol generation
 ■ Personnel to leave the room
 ■ Personnel should be monitored for symptoms of COVID 
on a regular basis.(6)
ACUTE CORONARY SYNDROMES
The phenomenon of decreased referrals of acute coronary 
syndrome (ACS) has been identified internationally during 
the COVID-19 pandemic and is likely to be of multifactorial 
origin.(7) Possible causes include a reduction in stressors such as 
traffic, pollution and smoking, or fear of presenting to poten-
tially contaminated hospital environments. The cardiovascular 
presentations of ACS patients with COVID-19 can be complex, 
with varying presentations of STEMI, stress cardiomyopathy, 
non-ischaemic cardiomyopathy, coronary spasm or non-specific 
myocardial injury.(8,9)
These considerations become more critical where staffing 
reserves are marginal, and where many South African hospitals 
are delivering PCI with a single catheterisation laboratory within 
a hospital facility. Careful evaluation is needed: which aspects 
of contemporary care are likely to bring greatest benefit to the 
patient and community, and which aspects are most likely to 
jeopardise the ongoing service delivery expected of our 
interventional units? 
STEMI
The global experience of managing STEMI during this pandemic 
has been encapsulated as “large delays in the small number of 
patients with STEMI seeking medical help”.(10) These delays are 
multi-level, inter-alia beginning with a reluctance of patients 
to come to the hospital, continuing to delays in diagnosis in the 
emergency room where triage is slowed by screening mea-
sures, and further exacerbated by time-consuming laboratory 
preparation measures, including the donning of PPE. These 
delays occur in a context where the well-established “time is 
muscle” paradigm demands very rapid decision-making and 
delivery of reperfusion therapy. 
Differential diagnosis
COVID-19, similar to other viral syndromes, may mimic a 
number of other conditions and each patient therefore requires 
a quick evaluation to decide if the presenting complaint is likely 
to be a primary coronary problem that may be improved by 
early invasive management. In one study, 40% of COVID-19 
patients with chest pain and ST elevation had no evidence 
of obstructive coronary disease at angiography.(11) Alternative 
diagnoses include myocarditis, Takotsubo cardiomyopathy and 
shock due to severe COVID-19 disease.(12,6) We may addi-
tionally expect increased susceptibility of chronic coronary 
artery disease patients to an acute myocardial event should 
they become COVID-19 infected – a phenomenon well 
described in relation to the influenza virus.(13) There is also 
evidence to suggest that patients with COVID-19 are more 
prone to thromboembolic events and pulmonary embolism 













Timing and reperfusion strategy
The COVID-19 pandemic should not compromise early 
reperfusion in all eligible patients (symptoms of ischaemia of 
<12 hours duration and persistent ST-segment elevation in at 
least two contiguous ECG leads.(15) In contemporary South 
African practice, relatively few patients usually have access to 
primary PCI and we are accustomed to fibrinolysis as first-line 
STEMI reperfusion therapy. For most South African hospitals 
this means that current reperfusion protocols remain applicable, 
though we may need to increase our flexibility as to where such 
treatments can be administered. 
The maximum time delay for primary PCI should remain 120 
minutes from first medical contact. Consideration should be 
given to a lysis first strategy, even in units traditionally pursuing 
primary PCI. This is likely to expose the least number of HCP 
to potential risk. Furthermore, where rapid testing is available 
patients can await test results, while effective reperfusion 
therapy has already been administered. In our context an 
estimated 60 minutes of extra delay in time to PCI (related to 
COVID-19-specific hospital adaptations) will likely delay many 
patients beyond the acceptable 120 minutes of PCI-related 
reperfusion delay.
It seems probable then that immediate triage to primary PCI 
will frequently require extra delays and costs to the system, as 
outlined in the Cath lab Preparation section. These obstacles 
may become prohibitive in centres without the luxury of a 
COVID-19 dedicated lab.
Pharmaco-invasive approach
Usually, guideline mandated pharmaco-invasive practice is to 
triage STEMI patients to the nearest PCI-capable hospital, after 
administration of thrombolytic reperfusion therapy at the 
peripheral hospital. The need for delivery of reperfusion therapy 
at the primary hospital must be highlighted at this time – 
COVID-19 brings this opportunity to re-evaluate our usual 
practices. STREAM-like protocols have, even pre-COVID-19, 
recommended that timeous fibrinolytic therapy should be given 
at first suitable point of medical contact.(16) Under pandemic 
conditions, transfer to a PCI-capable centre is a contentious 
issue and dependant on:
 ■ Availability of COVID-19 testing
 ■ Availability of early COVID-19 test results
 ■ Result of the thrombolytic therapy
 ■ Likely benefit of the intervention, considering the extent of 
myocardium at risk and time course of the infarct
These factors will differ between healthcare systems and need 
to be individualised, although the aim should still be to consider 
every patient for angiography within a reasonable time frame. 
Known COVID-19 negative status may expedite transfer 
arrangements and will certainly facilitate best use of facilities at 
the receiving hospital.
Failed lysis
There will be a significant group of STEMI patients in whom 
either fibrinolysis is contraindicated, or where it has failed to 
restore perfusion. This group is not insignificant: Post fibri-
nolysis, just over 50% of patients may require such rescue 
procedures.(17) Such patients, regardless of COVID-19 status, 
will require consideration for rescue PCI. 
COVID-19 complications
Where severe COVID-19 complications have limited prognosis 
more than the risk attributable to the infarct, it may be con-
sidered futile to proceed with angiography. Some virus com-
plications may contra-indicate the angiogram (severe renal 
dysfunction). We consider that a multidisciplinary team caring 
for the patient could assist in identifying such cases of likely 
medical futility, which may then be appropriately considered for 
compassionate conservative medical therapy.(8)
Multivessel disease
When a patient has non-culprit lesions that need intervention, 
operators should consider performing these at the same session 
to minimise the number of cath lab visits.
This complex weighing of risks will have to be patient-specific, 
with a clear understanding that we are operating in an area 
where we have little data. 
It must be clearly understood that supervision and leadership 
is important, and we must strive to spare overburdened 
caregivers with additional stressors in an already potentially 
damaging environment. Unit-specific treatment protocols can 
be constantly updated to reflect unique circumstances, and 
innovative use of new audio-visual networking technology can 
allow multidisciplinary team decisions to be agreed on – even 
in acute, complex revascularisation cases. Such sharing of 
decision-making may be anticipated to be beneficial to the 
attending physician, other staff, and certainly the patient. 
NSTE-ACS (NON ST ELEVATION ACUTE 
CORONARY SYNDROMES) 
The initial triage of patients presenting with chest pain syn-
dromes with ECG changes and/or elevated troponins should 
include consideration of other diagnostic possibilities, similar to 
those discussed under STEMI (above). 
As with STEMI, and for similar reasons, all patients presenting 
with NSTE-ACS should be screened for SARS-CoV2 at first 
medical contact, or as soon as possible thereafter. 
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Conventional management algorithms for NSTE-ACS identify 
categories of risk which define the likelihood of ensuing major 
adverse events, and the need for early invasive management 
strategies.(18) During this pandemic, accurate identification of 
the high risk patient becomes a critical step that will allow 
unusually limited resources to be accurately focused, and 
prevent low risk patients being exposed unnecessarily to 
hospital risks. 
Very high risk
The recently published EAPCI position statement summarises 
well known, very high risk features: “haemodynamic instability 
or cardiogenic shock, recurrent/ongoing chest pain refractory 
to medical therapy, life-threatening arrhythmias or cardiac 
arrest, mechanical complications of MI, acute heart failure, and 
recurrent intermittent ST-elevation”.(6) This cohort of patients 
should be managed with the same degree of urgency as the 
STEMI group and therefore also be presumed to be COVID-19 
positive until proven otherwise. If the medical facility of first 
contact cannot deliver angiography under these particular 
circumstances, such very high risk patients will require imme-
diate transfer to an appropriate COVID-19-lab-equipped 
facility. Angiography should not be delayed.(5) 
High risk
High risk patients include those that are troponin positive with 
dynamic ST segment changes, high Grace or TIMI scores or 
ongoing symptoms. If they can be stabilised for 24 hours until 
a virus test result is available, their ongoing management is 
much simplified, and they follow usual protocols.(6) Although 
there is benefit for early (within 24 hours) interventional pro-
cedures, it may often be reasonable to extend that 24 hour 
period until the result of a COVID-19 screening test is available. 
Clinical evaluation of the patient’s progress will dictate the 
permissible additional delay. 
Intermediate risk
Intermediate risk patients should be stabilised with optimal 
medical therapy, which may allow sufficient time to obtain 
virology results. This category includes patients with established 
NSTEMI based on cardiac troponins AND at least one of the 
following: diabetes mellitus, renal insufficiency, LVEF <40% or 
congestive heart failure, early post-infarction angina or prior 
PCI/CABG. Where coronary CT is available with appropriate 
experience and expertise in interpretation, these patients may 
be candidates for non-invasive evaluation to exclude high-risk 
anatomical features which may require invasive angiography 
such as left mainstem disease.(5) While this may reduce exposure 
of cath lab staff to COVID-19, this may be offset by the 
exposure to the CT angiography staff.
Low risk
Low risk patients should be discharged as soon as stabilised and 
followed with non-invasive ischaemia testing.
DRUGS IN THE CATH LAB
The use of investigational therapies in COVID-positive patients 
may influence drug selection and dosages in the cath lab. During 
the pandemic, the majority of patients taken to the lab will 
comprise high-risk ACS patients. ACS is a recognised pro-
thrombotic state and as we learn more about the COVID-19 
virus, it is being increasingly associated with a systemic coagu-
lopathy, and anticoagulation is linked to better survival among 
patients hospitalised with the condition.(14) Drug therapy will 
focus on adjustments to standard practice that need to be 
considered in the cath lab and will note the potential interactions 
with current antiviral therapies. 
Conscious Sedation
The usual pharmacological agents such as midazolam or 
diazepam are adequate, unless standard doses are exceeded, 
when respiratory depression becomes a concern. If opioids 
such as morphine or fentanyl are required for additional pain 
control, delayed gastric emptying or vomiting induced by these 
agents may impact on drug absorption. As anti-platelet P2Y12 
inhibitor loading for ACS often occurs in the lab at the time of 
intervention, those given opioids in a 2-hour span before or 
after the procedure may require bridging with a parenteral 
agent.(19) Glycoprotein llb/llla inhibitors may need to be initiated 
in the lab if the patient was not on chronic P2Y12 inhibitor 
therapy or insufficiently pre-treated with antiplatelet therapy 
prior to arrival in the cath lab. 
Anti-thrombotic treatment
The coagulation abnormalities observed in those with more 
severe COVID-19 infections, which include elevated D-dimer 
levels, mild thrombocytopenia, a prolongation of prothrombin 
and thrombin times, and disseminated intravascular coagula-
tion, as well as therapies administered prior to arrival in the 
cath lab, may impact on the selection and dosages used in our 
standard protocols. Listed below are the recommended 
regimens for patients undergoing primary PCI (Table II) for 
STEMI. The following medications may need adjustments if 
patients are on concomitant anti-viral therapies.
P2Y12 inhibitors
The anti-viral combination Lopinavir/Ritonavir causes increased 
serum concentrations of Ticagrelor through CYP3A4 inhibi-
tion and therefore poses an excess bleeding risk. Use of 
Ticagrelor has been discouraged in the USA and Canada during 
the pandemic. Clopidogrel, on the other hand, may not pro-
vide sufficient platelet inhibition during concomitant admini-
stration of Lopinavir/Ritonavir. Use of Prasugrel has been 
deemed safe.(5) 
Anti-coagulants
Heparin is preferred, as its anti-coagulant effect can be 
monitored. No major interactions have been reported with 













investigational drugs for COVID-19 and parenteral anti-coagu-
lants – except that heparin should not be co-administered with 
Azithromycin.
NOACs (non-vitamin K antagonist oral anticoagulants) such as 
rivaroxaban and apixaban, which may be used as part of a 
triple anti-thrombotic regimen in those with AF undergoing 
PCI, should be avoided in combination with Lopinavir/
Ritonavir, which acts by inhibition of cytochrome P450 3A4 
(CYP3A4) and/or P-glycoprotein (P-gp) activity – thereby 
increasing bleeding risk.(5)
Anti-arrhythmics in the cath lab
Prior to arrival in the cath lab, correction of reversible triggers 
for arrhythmia such as hypoxia, hypovolaemia, electrolyte 
abnormalities (hypokalaemia, hypomagnesaemia), metabolic 
acidosis and excessive use of catecholamines should be 
addressed. In patients with recurrent VT/VF or uncontrolled 
atrial fibrillation/atrial flutter, intravenous amiodarone is the 
anti-arrhythmic of choice. Its use in combination with hydroxy-
chloroquine and/or azithromycin should be avoided due to 
QT prolongation and a pro-arrhythmic potential, especially 
Torsades de Pointes VT. Therapy of Torsades VT includes 
withdrawal of QT-prolonging drugs, maintaining serum 
potassium >4.5mEq/L, IV magnesium supplementation and 
increasing heart rate (with IV Isoproterenol or temporary 
pacing).(5)
Cardiogenic shock 
Inotropes and/or vasopressors may be required to maintain 
hemodynamic stability in the cath lab. In critically ill COVID-19 
patients at risk for shock, a mixed aetiology of cardiogenic 
(large MI, severe myocarditis, LV dysfunction) and septic shock 
may need to be considered. Selecting the proper agent 
according to the patient’s clinical profile and limiting infusion to 
the shortest time and lowest dose possible, are all important.
Post ACS statins and RAAS-inhibitors
Co-administration of Lopinavir/Ritonavir with statins may 
result in myopathy. Simvastatin is contraindicated due to the 
risk of rhabdomyolysis. Atorvastatin or Rosuvastatin should be 
administered at the lowest possible dose.(12)
Angiotensin Converting Enzyme Inhibitor (ACEI)/Angiotensin 
Receptor Blockers (ARB) are often used in the post ACS 
setting. Although concern has been raised with the finding 
that these drugs increase levels of ACE-2, it is recommended 
that their use be continued for hypertension, heart failure and 
post -MI LV dysfunction.(5)
ELECTIVE CARDIOVASCULAR PROCEDURES 
DURING THE COVID-19 PANDEMIC
The knee-jerk reaction to the pandemic is to cancel all elective 
procedures until some point when it is considered safe to 
resume normal hospital activities. The underlying rationale 
seems solid: These procedures are not urgent and can there-
fore safely be postponed, patient contact to potentially infected 
individuals is reduced, healthcare personnel are not exposed 
to potential COVID-19 carriers, with a reduced infection risk, 
and hospital resources particularly ICU beds and ventilators are 
preserved for potentially sick COVID-19 patients.
This may be the correct approach in many specialities, but is 
not the case for many patients with underlying cardiovascular 
disease. Although a procedure may not necessarily be imme-
diately indicated to avert a life-threatening insult in the “elec-
tive” cohort of patients, deferral of a required intervention 
may lead to a deterioration of the underlying condition for a 
significant number of patients in this group.
TABLE II: Drug regimen in primary PCI
Drug Dosing Notes
Aspirin
Loading dose of 150 - 300mg orally as soon as possible for all patients without 
contraindications, then a maintenance dose of 75 - 100mg daily
Clopidogrel Loading dose of 600mg orally, then a maintenance dose of 75mg daily A more potent P2Y12 inhibitor 
(ticagrelor or prasugrel) is favoured. 
If these are not available or are 
contraindicated, then clopidogrel 
should be used. Administration before 
(or at latest at the time of) PCI is 
recommended and should be 
maintained for 12 months
Ticagrelor Loading dose of 180mg orally, then a maintenance dose of 90mg bd
Prasugrel
Loading dose of 60mg orally, then a maintenance dose of 10mg daily
• In patients weighing <60kg, the maintenance dose is reduced to 5mg daily
• Prasugrel is contra-indicated in patients with previous stroke
• In patients >/= 75 years of age, Prasugrel is not recommended
Unfractionated 
Heparin
• 70 - 100IU/kg IV bolus when no GPllb/llla inhibitors planned
• 50 - 70IU/kg IV bolus with GP llb/llla inhibitors
Routine use of Heparin is 
recommended 1C. Use of Enoxaparin 
IV is a lla recommendation
Enoxaparin 0.5mg/kg IV bolus
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The timing of so-called “elective” procedures in this patient 
population therefore requires more thoughtful consideration. 
Time delay of elective procedures
The vast majority of therapeutic procedures in patients with 
CV disease are not optional and cannot be postponed indefi-
nitely. Unfortunately, there are no data to guide us regarding 
the acceptable delay of a therapeutic intervention in patients 
with cardiovascular disease. Clinicians will therefore have to 
use their judgement and knowledge of the natural history of 
the disease to assess how long a patient could potentially wait 
to have a procedure. Table III shows a classification of timing 
for common cardiovascular interventions.
Risk of patient infection during hospital stay
The virus has to date not been shown to be transferred via 
long-range airborne transmission. The secondary attack rate 
for household contacts is 10% - 15%.(20,21,22) The risk of trans-
mission otherwise is unknown; in particular: it is not certain 
what the risk of transfer between 2 masked individuals is who 
practice good hand hygiene. Overall it seems the risk of a 
patient contracting the virus in hospital with the necessary pre-
cautions would be very low. 
Risk to HCP
The easiest way to mitigate the risk of HCP infection would be 
to do procedures only on COVID-19 negative patients or 
patients who have fully recovered from the infection. However, 
asymptomatic COVID-19 patients are not uncommon (up to 
50% in some studies).(23) In addition, patients who have con-
tracted the virus are already infectious a few days prior to 
developing symptoms and can thus unwittingly infect those in 
contact with them.(24)
Given the cost and the delay in obtaining test results, per-
forming a routine COVID-19 screening nasal swab on every 
asymptomatic patient undergoing an elective procedure is not 
feasible in most healthcare settings in South Africa. Clinical 
screening looking at a combination of symptoms is possibly 
helpful, but the overall sensitivity to detect patients with 
COVID-19 is likely to be poor, as patients may be asymptomatic 
while infective. 
Nonetheless the risk of transmission to the HCP for most 
cardiovascular procedures (i.e. procedures in which there is a 
low exposure to respiratory secretions and aerosol produc-
tion) is low, provided basic strategies to prevent infection 
(surgical masks for both patient and HCPs and good hand 
hygiene) are employed.(25,26)
It would therefore be reasonable to proceed with interven-
tions where the risk of virus exposure is low. This would be the 
case for most routine procedures performed in the angio suite.
Facility resource utilisation
As it is likely that the hospital resources need to be diverted to 
sick COVID-19 patients, it is important to preserve ICU beds. 
Procedures on patients who are expected to have a significant 
peri-procedural ICU stay, should be deferred if possible. 
Hospital stay should be as short as possible in order to minimise 
the chance of infection of either patients or HCP. 
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TABLE III: Timing of cardiovascular procedures.
Category Time Example
Urgent <1 month Severe symptomatic valve disease (especially AS or MS), non-infarct-related artery PCI post-AMI
Essential 1 - 3 months Subacute valve procedures, transplant workup
Elective 3 - 6 months ASD, PDA, PFO, LAA closure
Optional Revascularisation of patients with chronic CAD
FIGURE 1: Decision making for elective procedures sum-
marised as a balance between risks.
Risk of patient NOT 
undergoing an 
essential procedure


















Figure 1 provides a pictorial summary of some of the issues 
which need to be considered prior to deciding to proceed to 
the cath lab, and Figure 2 provides an algorithm to help guide 
the decisions once the issues have been weighed up. 
CONCLUSION
Projections by the WHO are that the COVID-19 pandemic 
will persist into the foreseeable future, until either a vaccine is 
widely available or there is widespread “herd” immunity. During 
this period we, as interventional cardiologists in South Africa, 
will have to become acquainted with a new paradigm that 
requires us to prepare and plan well beyond the technical 
interventional details and anatomical complexities of our 
patient and consider the safety of the entire team of healthcare 
professionals and others who work in the cath lab. In this 
perspective review, we as the SASCI executive committee, 
have attempted to provide a base of core issues to consider as 
you adapt your practice to the new environment. 
Conflict of interest: none declared.
FIGURE 2: Flow diagram to delineate management of patients requiring elective procedures.








If testing easily available wait 
for result to proceed
If testing not easily available, 
WHO risk stratify the patient
Is patient a suspect of probable case?
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